Stereotaxis, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 54/100
What the filing says
Stereotaxis reported Q2 2026 total revenue of $7.7M (down 12.8% YoY), with robotic catheter revenue surpassing $1M in the quarter, representing 270% sequential growth. The company completed its previously announced Robocath acquisition and achieved FDA clearance for Synchrony digital OR systems in April. System revenue declined to $1.5M from $3.0M YoY due to lack of robotic system deliveries, offset partially by initial Synchrony sales; recurring revenue increased to $6.2M from $5.8M YoY. Net loss was $4.5M for Q2 2026 vs. $3.8M prior year; cash position $10.5M with no debt. Management forecasts cash flow profitability in H1 2027.
Why this rating
Robocath acquisition and emerging product revenues represent meaningful strategic progress, but modest absolute scale (~$1M catheter revenue = 0.67% of company market cap) and near-term operating losses with declining system revenue offset positive momentum. Relative to $150M company size, developments are notable but not trajectory-altering yet.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.